Skip to main content
Erschienen in: International Urogynecology Journal 4/2009

01.04.2009 | Review

Pharmacotherapy of urinary incontinence

verfasst von: Anastasios Athanasopoulos, Petros Perimenis

Erschienen in: International Urogynecology Journal | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

The pathophysiology of urinary incontinence (UI) involves an overactive detrusor (DOA) or an incompetent urethral sphincter. Therefore, the three most common types of UI are stress urinary incontinence (SUI), urge urinary incontinence (UUI), or a combination of stress and urge known as mixed urinary incontinence (MUI). Pharmacotherapy represents a recognized option for the treatment of different types of UI. A literature search of Medline publications on pharmacological treatment of urinary incontinence until 2008 was performed. Relevant data from recently published literature were included. Anticholinergics are the cornerstone of UUI treatment, whereas serotonin and norepinephrine re-uptake inhibitors represent an option for SUI treatment. A significant percentage of patients with UI, mainly those with UUI and MUI, can be treated successfully with pharmacotherapy.
Literatur
1.
Zurück zum Zitat Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international Continence society. Neurourol Urodyn 21:167–178PubMedCrossRef Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A (2002) Standardisation Sub-committee of the International Continence Society. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international Continence society. Neurourol Urodyn 21:167–178PubMedCrossRef
2.
Zurück zum Zitat Thomas TM, Plymat KR, Blannin J, Meade TW (1980) Prevalence of urinary incontinence. Br Med J 281(6250):1243–1245PubMed Thomas TM, Plymat KR, Blannin J, Meade TW (1980) Prevalence of urinary incontinence. Br Med J 281(6250):1243–1245PubMed
3.
Zurück zum Zitat Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidem 53(11):1150–1157CrossRef Hannestad YS, Rortveit G, Sandvik H, Hunskaar S (2000) Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidem 53(11):1150–1157CrossRef
4.
Zurück zum Zitat Milsom I (2006) Epidemiology of stress, urgency, and mixed incontinence: where do the boundaries cross? Eur Urol Suppl 5(16):842–848CrossRef Milsom I (2006) Epidemiology of stress, urgency, and mixed incontinence: where do the boundaries cross? Eur Urol Suppl 5(16):842–848CrossRef
5.
Zurück zum Zitat Herzog AR, Fultz NH (1990) Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 38:273–278PubMed Herzog AR, Fultz NH (1990) Prevalence and incidence of urinary incontinence in community-dwelling populations. J Am Geriatr Soc 38:273–278PubMed
6.
Zurück zum Zitat Schoulman C, Claesm H, Mattijs J (1997) Urinary incontinence in Belgium: a population-based epidemiological survey. Eur Urol 32:315–320 Schoulman C, Claesm H, Mattijs J (1997) Urinary incontinence in Belgium: a population-based epidemiological survey. Eur Urol 32:315–320
7.
Zurück zum Zitat Urt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D (1995) Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25(3):305–313 Urt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D (1995) Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 25(3):305–313
8.
Zurück zum Zitat Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Diabetes Care 27:1047–1053PubMedCrossRef Wild S, Roglic G, Green A, Sicree R, King H (2004) Global prevalence of diabetes. Diabetes Care 27:1047–1053PubMedCrossRef
9.
Zurück zum Zitat Silverstein B (1999) Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am J Psychiatry 156:480–482PubMed Silverstein B (1999) Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am J Psychiatry 156:480–482PubMed
10.
Zurück zum Zitat Odeyemi IA, Dakin HA, O'Donnell RA, Warner J, Jacobs A, Dasgupta P (2006) Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 60(8):949–958PubMedCrossRef Odeyemi IA, Dakin HA, O'Donnell RA, Warner J, Jacobs A, Dasgupta P (2006) Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. Int J Clin Pract 60(8):949–958PubMedCrossRef
11.
Zurück zum Zitat Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3):461–465PubMedCrossRef Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T (2004) Costs of urinary incontinence and overactive bladder in the United States: a comparative study. Urology 63(3):461–465PubMedCrossRef
12.
Zurück zum Zitat Debruyne FMJ, Heesakkers JPFA (2004) Clinical and socioeconomic relevance of overactive bladder. Urology 63:42–44PubMedCrossRef Debruyne FMJ, Heesakkers JPFA (2004) Clinical and socioeconomic relevance of overactive bladder. Urology 63:42–44PubMedCrossRef
13.
Zurück zum Zitat Darkow T, Fontes CL, Williamson TE (2005) Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 25:511–519PubMedCrossRef Darkow T, Fontes CL, Williamson TE (2005) Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy 25:511–519PubMedCrossRef
14.
Zurück zum Zitat Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallet D (2005) Employees with overactive bladder: work loss burden. J Occup Environ Med 47:439–446PubMedCrossRef Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallet D (2005) Employees with overactive bladder: work loss burden. J Occup Environ Med 47:439–446PubMedCrossRef
15.
Zurück zum Zitat Morris V, Wagg A (2007) Lower urinary tract symptoms, incontinence and falls in elderly people: time for an intervention study. Int J Clin Pract 61(2):320–323PubMedCrossRef Morris V, Wagg A (2007) Lower urinary tract symptoms, incontinence and falls in elderly people: time for an intervention study. Int J Clin Pract 61(2):320–323PubMedCrossRef
16.
Zurück zum Zitat Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urology 20(6):327–336 Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urology 20(6):327–336
17.
Zurück zum Zitat Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 87(9):760–766 Erratum in: Br J Urol Int 88(7):807 Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 87(9):760–766 Erratum in: Br J Urol Int 88(7):807
18.
Zurück zum Zitat Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315PubMedCrossRef Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1315PubMedCrossRef
19.
Zurück zum Zitat Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395PubMedCrossRef Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I (2008) The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 101(11):1388–1395PubMedCrossRef
20.
Zurück zum Zitat Jackson S (1997) The patient with an overactive bladder—symptoms and quality-of-life issues. Urology 50(6A Suppl):18–22PubMedCrossRef Jackson S (1997) The patient with an overactive bladder—symptoms and quality-of-life issues. Urology 50(6A Suppl):18–22PubMedCrossRef
21.
Zurück zum Zitat Chapple C (2006) Classification of mixed incontinence. Eur Urol Supp 5(16):837–841CrossRef Chapple C (2006) Classification of mixed incontinence. Eur Urol Supp 5(16):837–841CrossRef
22.
Zurück zum Zitat Chu FM, Dmochowski R (2006) Pathophysiology of overactive bladder. AJM 119(3A):3S–8SCrossRef Chu FM, Dmochowski R (2006) Pathophysiology of overactive bladder. AJM 119(3A):3S–8SCrossRef
24.
Zurück zum Zitat Steers DS (2002) Pathophysiology of overactive bladder and urinary incontinence. Rev Urol 4(suppl 4):S7–S18PubMed Steers DS (2002) Pathophysiology of overactive bladder and urinary incontinence. Rev Urol 4(suppl 4):S7–S18PubMed
25.
Zurück zum Zitat Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurology 3(1):46–53PubMedCrossRef Andersson KE (2004) Antimuscarinics for treatment of overactive bladder. Lancet Neurology 3(1):46–53PubMedCrossRef
26.
27.
Zurück zum Zitat Robinson D, Cardozo L (2004) The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 13(10):1339–1348PubMedCrossRef Robinson D, Cardozo L (2004) The emerging role of solifenacin in the treatment of overactive bladder. Expert Opin Investig Drugs 13(10):1339–1348PubMedCrossRef
28.
Zurück zum Zitat Chapple CR (2004) Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13(11):1493–1500PubMedCrossRef Chapple CR (2004) Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder. Expert Opin Investig Drugs 13(11):1493–1500PubMedCrossRef
29.
Zurück zum Zitat Hofner K, Oelke M, Machtens S, Grunewald V (2001) Trospium chloride—an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urology 19(5):336–343CrossRef Hofner K, Oelke M, Machtens S, Grunewald V (2001) Trospium chloride—an effective drug in the treatment of overactive bladder and detrusor hyperreflexia. World J Urology 19(5):336–343CrossRef
30.
Zurück zum Zitat Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urology 19(5):319–323CrossRef Andersson KE, Chapple CR (2001) Oxybutynin and the overactive bladder. World J Urology 19(5):319–323CrossRef
31.
Zurück zum Zitat De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169(5):1892–1895PubMedCrossRef De Wachter S, Wyndaele JJ (2003) Intravesical oxybutynin: a local anesthetic effect on bladder C afferents. J Urol 169(5):1892–1895PubMedCrossRef
32.
Zurück zum Zitat Madersbacher H, Murtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urology 19(5):324–335CrossRef Madersbacher H, Murtz G (2001) Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic). World J Urology 19(5):324–335CrossRef
33.
Zurück zum Zitat Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 326(7394):841–844CrossRef Herbison P, Hay-Smith J, Ellis G, Moore K (2003) Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br Med J 326(7394):841–844CrossRef
34.
Zurück zum Zitat Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48(1):5–26PubMedCrossRef Chapple C, Khullar V, Gabriel Z, Dooley JA (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 48(1):5–26PubMedCrossRef
35.
Zurück zum Zitat Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8):931–937PubMedCrossRef Haab F, Castro-Diaz D (2005) Persistence with antimuscarinic therapy in patients with overactive bladder. Int J Clin Pract 59(8):931–937PubMedCrossRef
36.
Zurück zum Zitat Kirby M, Artibani W, Cardozo L, Chapple C, Diaz DC, De Ridder D, Espuna-Pons M, Haab F, Kelleher C, Milsom I, Van Kerrebroeck P, Vierhout M, Wagg A (2006) Overactive bladder: the importance of new guidance. Int J Clin Pract 60(10):1263–1271PubMedCrossRef Kirby M, Artibani W, Cardozo L, Chapple C, Diaz DC, De Ridder D, Espuna-Pons M, Haab F, Kelleher C, Milsom I, Van Kerrebroeck P, Vierhout M, Wagg A (2006) Overactive bladder: the importance of new guidance. Int J Clin Pract 60(10):1263–1271PubMedCrossRef
37.
Zurück zum Zitat Abrams P, Freeman R, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81(6):801–810PubMed Abrams P, Freeman R, Anderstrom C, Mattiasson A (1998) Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 81(6):801–810PubMed
38.
Zurück zum Zitat Giannitsas K, Perimenis P, Athanasopoulos A, Gyftopoulos K, Nikiforidis G, Barbalias G (2004) Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 46(6):776–782PubMedCrossRef Giannitsas K, Perimenis P, Athanasopoulos A, Gyftopoulos K, Nikiforidis G, Barbalias G (2004) Comparison of the efficacy of tolterodine and oxybutynin in different urodynamic severity grades of idiopathic detrusor overactivity. Eur Urol 46(6):776–782PubMedCrossRef
39.
Zurück zum Zitat Abrams P, Swift S (2005) Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 48(3):483–487PubMed Abrams P, Swift S (2005) Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur Urol 48(3):483–487PubMed
40.
Zurück zum Zitat Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740–764PubMedCrossRef Novara G, Galfano A, Secco S, D’Elia C, Cavalleri S, Ficarra V, Artibani W (2008) A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 54:740–764PubMedCrossRef
41.
Zurück zum Zitat Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner KA (1999) Placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br J Urol International 84(6):646–651 Madersbacher H, Halaska M, Voigt R, Alloussi S, Hofner KA (1999) Placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. Br J Urol International 84(6):646–651
42.
Zurück zum Zitat Junemann KP, Halaska M, Rittstein T, Murtz G, Schnabel F, Brunjes R, Nurkiewicz W (2005) Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 48(3):478–482PubMed Junemann KP, Halaska M, Rittstein T, Murtz G, Schnabel F, Brunjes R, Nurkiewicz W (2005) Propiverine versus tolterodine: efficacy and tolerability in patients with overactive bladder. Eur Urol 48(3):478–482PubMed
43.
Zurück zum Zitat Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J, for the STAR study group (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48(3):464–470PubMed Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J, for the STAR study group (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48(3):464–470PubMed
44.
Zurück zum Zitat Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J, STAR study group (2007) Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52(4):1195–1203PubMedCrossRef Chapple CR, Fianu-Jonsson A, Indig M, Khullar V, Rosa J, Scarpa RM, Mistry A, Wright DM, Bolodeoku J, STAR study group (2007) Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52(4):1195–1203PubMedCrossRef
45.
Zurück zum Zitat Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171(6):2311–2315PubMedCrossRef Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, Auerbach S, Trospium Study Group (2004) Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 171(6):2311–2315PubMedCrossRef
46.
Zurück zum Zitat Junemann KP, Al-Shukri S (2000) Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double blind, placebo controlled multicenter clinical trial. Neurourl Urodyn 19:488–493 Junemann KP, Al-Shukri S (2000) Efficacy and tolerability of trospium chloride and tolterodine in 234 patients with urge-syndrome: a double blind, placebo controlled multicenter clinical trial. Neurourl Urodyn 19:488–493
47.
Zurück zum Zitat Nitti V, Wiatrak M, Kreitman L, Lipsitz D (2005) Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB)Q results of a phase 2 trial. Paper presented at International Continence Society Montreal, Canada, August 31–September 2 Nitti V, Wiatrak M, Kreitman L, Lipsitz D (2005) Fesoterodine is an effective antimuscarinic for patients with overactive bladder (OAB)Q results of a phase 2 trial. Paper presented at International Continence Society Montreal, Canada, August 31–September 2
48.
Zurück zum Zitat Chaple C, Kerrebrock PV, Tubaro A, Haag-Molkenteller c, Forst HT, Massow U, Wang J, Brodsky M (2007) Clinical efficacy, safety, and tolerability of once—daily fesoterodine in subjects with overactive bladder. Eur Urol 52(4):1204–1212CrossRef Chaple C, Kerrebrock PV, Tubaro A, Haag-Molkenteller c, Forst HT, Massow U, Wang J, Brodsky M (2007) Clinical efficacy, safety, and tolerability of once—daily fesoterodine in subjects with overactive bladder. Eur Urol 52(4):1204–1212CrossRef
49.
Zurück zum Zitat Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE (1999) Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161(5):1551–1555PubMedCrossRef Millard R, Tuttle J, Moore K, Susset J, Clarke B, Dwyer P, Davis BE (1999) Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J Urol 161(5):1551–1555PubMedCrossRef
50.
Zurück zum Zitat Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6(3):243–262PubMed Yarker YE, Goa KL, Fitton A (1995) Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 6(3):243–262PubMed
51.
Zurück zum Zitat Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562PubMedCrossRef Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54(3):543–562PubMedCrossRef
52.
Zurück zum Zitat Athanasopoulos A, Perimenis P (2005) Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Exp Opin Pharmac 6(14):2429–2433CrossRef Athanasopoulos A, Perimenis P (2005) Efficacy of the combination of an alpha1-blocker with an anticholinergic agent in the treatment of lower urinary tract symptoms associated with bladder outlet obstruction. Exp Opin Pharmac 6(14):2429–2433CrossRef
53.
Zurück zum Zitat Hunsballe JM, Djurhuus JC (2001) Clinical options for imipramine in the management of urinary incontinence. Urol Res 29(2):118–125PubMedCrossRef Hunsballe JM, Djurhuus JC (2001) Clinical options for imipramine in the management of urinary incontinence. Urol Res 29(2):118–125PubMedCrossRef
54.
Zurück zum Zitat Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J (2002) Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 89(9):855–862PubMedCrossRef Mattiasson A, Abrams P, Van Kerrebroeck P, Walter S, Weiss J (2002) Efficacy of desmopressin in the treatment of nocturia: a double-blind placebo-controlled study in men. BJU Int 89(9):855–862PubMedCrossRef
55.
Zurück zum Zitat Lose G, Lalos O, Freeman RM, van Kerrebroeck P, Nocturia Study Group (2003) Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 189(4):1106–1113PubMedCrossRef Lose G, Lalos O, Freeman RM, van Kerrebroeck P, Nocturia Study Group (2003) Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebo-controlled study in women. Am J Obstet Gynecol 189(4):1106–1113PubMedCrossRef
56.
Zurück zum Zitat Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP (2004) Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 93(7):996–1000PubMedCrossRef Robinson D, Cardozo L, Akeson M, Hvistendahl G, Riis A, Norgaard JP (2004) Antidiuresis: a new concept in managing female daytime urinary incontinence. BJU Int 93(7):996–1000PubMedCrossRef
57.
Zurück zum Zitat Park JT, Song C, Choo M (2002) The effect of bladder training, tolterodine and bladder training with tolterodine in female patients with overactive bladder: a prospective randomized study. Neurol Urodyn 21:434–438 Park JT, Song C, Choo M (2002) The effect of bladder training, tolterodine and bladder training with tolterodine in female patients with overactive bladder: a prospective randomized study. Neurol Urodyn 21:434–438
58.
Zurück zum Zitat Song C, Park JT, Heo KO, Lee KS, Choo MS (2006) Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 21(6):1060–1063PubMedCrossRef Song C, Park JT, Heo KO, Lee KS, Choo MS (2006) Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci 21(6):1060–1063PubMedCrossRef
59.
Zurück zum Zitat Viktrup L (2002) Female stress and urge incontinence in family practice: insight into the lower urinary tract. Int J Clin Pract 56(9):694–700PubMed Viktrup L (2002) Female stress and urge incontinence in family practice: insight into the lower urinary tract. Int J Clin Pract 56(9):694–700PubMed
60.
Zurück zum Zitat Cardozo L (2004) New developments in the management of stress urinary incontinence. Br J Urol Int 94(suppl 1):1–3 Cardozo L (2004) New developments in the management of stress urinary incontinence. Br J Urol Int 94(suppl 1):1–3
61.
Zurück zum Zitat Pesce F (2004) Current management of stress urinary incontinence. Br J Urol Int 94(suppl 1):8–13 Pesce F (2004) Current management of stress urinary incontinence. Br J Urol Int 94(suppl 1):8–13
62.
Zurück zum Zitat Viktrup L, Bump RC (2003) Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 19(6):485–490PubMedCrossRef Viktrup L, Bump RC (2003) Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 19(6):485–490PubMedCrossRef
63.
Zurück zum Zitat Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J, Kawabe K (1998) Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123(7):1289–1293PubMedCrossRef Nasu K, Moriyama N, Fukasawa R, Tsujimoto G, Tanaka T, Yano J, Kawabe K (1998) Quantification and distribution of alpha1-adrenoceptor subtype mRNAs in human proximal urethra. Br J Pharmacol 123(7):1289–1293PubMedCrossRef
64.
Zurück zum Zitat Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, Haab F, Vela Navarrete R (1999) The pharmacological treatment of urinary incontinence. Br J Urol Int 84(9):923–947 Andersson KE, Appell R, Cardozo LD, Chapple C, Drutz HP, Finkbeiner AE, Haab F, Vela Navarrete R (1999) The pharmacological treatment of urinary incontinence. Br J Urol Int 84(9):923–947
65.
Zurück zum Zitat Alhasso A, Glazener CM, Pickard R, N'Dow J (2003) Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2:CD001842PubMed Alhasso A, Glazener CM, Pickard R, N'Dow J (2003) Adrenergic drugs for urinary incontinence in adults. Cochrane Database Syst Rev 2:CD001842PubMed
66.
Zurück zum Zitat Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343(25):1826–1832PubMedCrossRef Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI (2000) Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343(25):1826–1832PubMedCrossRef
67.
Zurück zum Zitat Fleming GA (2000) The FDA, regulation, and the risk of stroke. N Engl J Med 343(25):1886–1887PubMedCrossRef Fleming GA (2000) The FDA, regulation, and the risk of stroke. N Engl J Med 343(25):1886–1887PubMedCrossRef
68.
69.
Zurück zum Zitat Grady D, Brown JS, Vittinghoff E (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen? Progestin Replacement study. Obst Gynecol 97:116–120CrossRef Grady D, Brown JS, Vittinghoff E (2001) Postmenopausal hormones and incontinence: the Heart and Estrogen? Progestin Replacement study. Obst Gynecol 97:116–120CrossRef
70.
Zurück zum Zitat Grodstein F, Lifford K, Resnick NM (2004) Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 103:254–260PubMed Grodstein F, Lifford K, Resnick NM (2004) Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynecol 103:254–260PubMed
71.
Zurück zum Zitat Michel MC, Petes SLM (2004) Role of serotonin and noradrenaline in stress urinary incontinence. Br J Urol Int 94(suppl 1):23–30 Michel MC, Petes SLM (2004) Role of serotonin and noradrenaline in stress urinary incontinence. Br J Urol Int 94(suppl 1):23–30
72.
Zurück zum Zitat Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharm Exp Ther 274(2):1014–1024 Thor KB, Katofiasc MA (1995) Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharm Exp Ther 274(2):1014–1024
73.
Zurück zum Zitat Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine urinary incontinence study group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263 Erratum in: J Urol (2004); 171(1):360PubMedCrossRef Dmochowski RR, Miklos JR, Norton PA, Zinner NR, Yalcin I, Bump RC (2003) Duloxetine urinary incontinence study group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. J Urol 170:1259–1263 Erratum in: J Urol (2004); 171(1):360PubMedCrossRef
74.
Zurück zum Zitat Kerrebroeck PV (2004) Duloxetin: an innovative approach for treating stress urinary incontinence. Br J Urol International 94(suppl 1):31–37 Kerrebroeck PV (2004) Duloxetin: an innovative approach for treating stress urinary incontinence. Br J Urol International 94(suppl 1):31–37
75.
Zurück zum Zitat Thor KB, Kirby M, Viktrup L (2007) Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61(8):1349–1355PubMedCrossRef Thor KB, Kirby M, Viktrup L (2007) Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61(8):1349–1355PubMedCrossRef
76.
Zurück zum Zitat Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine urinary incontinence study group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstetr Gyn 187(1):40–48CrossRef Norton PA, Zinner NR, Yalcin I, Bump RC (2002) Duloxetine urinary incontinence study group. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstetr Gyn 187(1):40–48CrossRef
77.
Zurück zum Zitat Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC (2005) Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173(5):1647–1653PubMedCrossRef Ghoniem GM, Van Leeuwen JS, Elser DM, Freeman RM, Zhao YD, Yalcin I, Bump RC (2005) Duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. J Urol 173(5):1647–1653PubMedCrossRef
78.
Zurück zum Zitat Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J (2007) Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 51:67–74PubMedCrossRef Mariappan P, Alhasso A, Ballantyne Z, Grant A, N’Dow J (2007) Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 51:67–74PubMedCrossRef
79.
Zurück zum Zitat Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC (2007) Duloxetine dose escalation study group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 18(8):919–929PubMedCrossRef Castro-Diaz D, Palma PC, Bouchard C, Haab F, Hampel C, Carone R, Zepeda Contreras S, Rodriguez Ginorio H, Voss S, Yalcin I, Bump RC (2007) Duloxetine dose escalation study group. Effect of dose escalation on the tolerability and efficacy of duloxetine in the treatment of women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 18(8):919–929PubMedCrossRef
80.
Zurück zum Zitat Cardozo L (2006) Pharmacotherapy in stress and mixed incontinence. Eur Urol Suppl 5:854–859CrossRef Cardozo L (2006) Pharmacotherapy in stress and mixed incontinence. Eur Urol Suppl 5:854–859CrossRef
81.
Zurück zum Zitat Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E (2004) Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64:269–274PubMedCrossRef Khullar V, Hill S, Laval KU, Schiøtz HA, Jonas U, Versi E (2004) Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial. Urology 64:269–274PubMedCrossRef
82.
Zurück zum Zitat Smith KE, McGuire E (2008) Mixed urinary incontinence. In: Raz S, Rodriguez LV (eds) Female urology. 3rd edn. Elsevier, Philadelphia, pp 477–485 Smith KE, McGuire E (2008) Mixed urinary incontinence. In: Raz S, Rodriguez LV (eds) Female urology. 3rd edn. Elsevier, Philadelphia, pp 477–485
83.
Zurück zum Zitat Andersson KE, Chapple C, et al (2008) Drug treatment committee. 4th ICI Paris Andersson KE, Chapple C, et al (2008) Drug treatment committee. 4th ICI Paris
Metadaten
Titel
Pharmacotherapy of urinary incontinence
verfasst von
Anastasios Athanasopoulos
Petros Perimenis
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
International Urogynecology Journal / Ausgabe 4/2009
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-008-0761-1

Weitere Artikel der Ausgabe 4/2009

International Urogynecology Journal 4/2009 Zur Ausgabe

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.